Ellipses Pharma

Executive Summary

Ellipses Pharma is a London-based, clinical-stage oncology drug development company founded in 2018. The company employs an innovative, capital-efficient model to accelerate the development of cancer treatments by in-licensing and advancing promising assets. By focusing on a broad range of cancers, mechanisms, and molecule types, Ellipses aims to address significant unmet medical needs. Its asset-light strategy allows it to efficiently progress multiple programs through early-stage clinical development without the overhead of a traditional biopharma, positioning it to create value through strategic partnerships or eventual portfolio maturation. Currently in Phase 1 development, Ellipses Pharma is advancing its lead assets through initial clinical trials. While specific pipeline details are undisclosed, the company's model suggests several near-term milestones, including dose-escalation data readouts, expansion cohort initiations, and potential new licensing agreements. The success of these early-stage trials and the company's ability to demonstrate proof-of-concept will be critical for securing further financing and partnerships. Given the early stage, the risk profile is elevated, but the capital-efficient approach offers a differentiated path to de-risking assets with lower upfront costs.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead asset40% success
• Q4 2026Initiation of a new Phase 1 trial for an in-licensed candidate80% success
• Q3 2026Announcement of a new licensing agreement or partnership50% success